메뉴 건너뛰기




Volumn 153, Issue 6, 2010, Pages 413-415

Conflicting evidence: What's a clinician to do?

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; ROFECOXIB; ROSIGLITAZONE; TICAGRELOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

EID: 77957347819     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-6-201009210-00011     Document Type: Editorial
Times cited : (5)

References (22)
  • 1
    • 77957372907 scopus 로고    scopus 로고
    • Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. A nationwide cohort study
    • Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. A nationwide cohort study. Ann Intern Med. 2010;153:378-86.
    • (2010) Ann Intern Med , vol.153 , pp. 378-386
    • Charlot, M.1    Ahlehoff, O.2    Norgaard, M.L.3    Jørgensen, C.H.4    Sørensen, R.5    Abildstrøm, S.Z.6
  • 2
    • 64849116567 scopus 로고    scopus 로고
    • Abstract 3999: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial
    • Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, et al. Abstract 3999: Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation. 2008;118:S815.
    • (2008) Circulation , vol.118
    • Dunn, S.P.1    Macaulay, T.E.2    Brennan, D.M.3    Campbell, C.L.4    Charnigo, R.J.5    Smyth, S.S.6
  • 3
    • 61549124132 scopus 로고    scopus 로고
    • Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
    • PMID: 19258584
    • Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-44. [PMID: 19258584]
    • (2009) JAMA , vol.301 , pp. 937-944
    • Ho, P.M.1    Maddox, T.M.2    Wang, L.3    Fihn, S.D.4    Jesse, R.L.5    Peterson, E.D.6
  • 4
    • 62649164844 scopus 로고    scopus 로고
    • A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
    • PMID: 19176635
    • Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8. [PMID: 19176635]
    • (2009) CMAJ , vol.180 , pp. 713-718
    • Juurlink, D.N.1    Gomes, T.2    Ko, D.T.3    Szmitko, P.E.4    Austin, P.C.5    Tu, J.V.6
  • 5
    • 70249139788 scopus 로고    scopus 로고
    • Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
    • PMID: 19726078
    • O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-97. [PMID: 19726078]
    • (2009) Lancet , vol.374 , pp. 989-997
    • O'Donoghue, M.L.1    Braunwald, E.2    Antman, E.M.3    Murphy, S.A.4    Bates, E.R.5    Rozenman, Y.6
  • 6
    • 77950895115 scopus 로고    scopus 로고
    • Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study
    • PMID: 20231564
    • Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152:337-45. [PMID: 20231564]
    • (2010) Ann Intern Med , vol.152 , pp. 337-345
    • Ray, W.A.1    Murray, K.T.2    Griffin, M.R.3    Chung, C.P.4    Smalley, W.E.5    Hall, K.6
  • 7
    • 70249118631 scopus 로고    scopus 로고
    • London: European Medicines Agency; Accessed at on 13 August 2010
    • European Medicines Agency. Public Statement on Interaction between clopidogrel and proton-pump inhibitors. London: European Medicines Agency; 2010. Accessed at www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/17494810en.pdf on 13 August 2010.
    • (2010) Public Statement on Interaction between Clopidogrel and Proton-pump Inhibitors
  • 9
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators PMID: 11519503
    • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. [PMID: 11519503]
    • (2001) N Engl J Med , vol.345 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 10
    • 0037145863 scopus 로고    scopus 로고
    • Clopidogrel for the Reduction of Events during Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • CREDO Investigators. PMID: 12435254
    • Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20. [PMID: 12435254]
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1    Berger, P.B.2    Mann III, J.T.3    Fry, E.T.4    DeLago, A.5    Wilmer, C.6
  • 11
    • 33645861080 scopus 로고    scopus 로고
    • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    • CHARISMA Investigators. PMID: 16531616
    • Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17. [PMID: 16531616]
    • (2006) N Engl J Med , vol.354 , pp. 1706-1717
    • Bhatt, D.L.1    Fox, K.A.2    Hacke, W.3    Berger, P.B.4    Black, H.R.5    Boden, W.E.6
  • 12
    • 77953133377 scopus 로고    scopus 로고
    • Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention
    • PMID: 20538118
    • Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol. 2010;105:1705-9. [PMID: 20538118]
    • (2010) Am J Cardiol , vol.105 , pp. 1705-1709
    • Huang, C.C.1    Chen, Y.C.2    Leu, H.B.3    Chen, T.J.4    Lin, S.J.5    Chan, W.L.6
  • 13
    • 71749087343 scopus 로고    scopus 로고
    • Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data
    • PMID: 20006130
    • Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-74. [PMID: 20006130]
    • (2009) Lancet , vol.374 , pp. 1967-1974
    • Sørensen, R.1    Hansen, M.L.2    Abildstrom, S.Z.3    Hvelplund, A.4    Andersson, C.5    Jørgensen, C.6
  • 14
    • 34548314463 scopus 로고    scopus 로고
    • Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding
    • DOI 10.1503/cmaj.070186
    • Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347-51. [PMID: 17698822] (Pubitemid 47339530)
    • (2007) Canadian Medical Association Journal , vol.177 , Issue.4 , pp. 347-351
    • Delaney, J.A.1    Opatrny, L.2    Brophy, J.M.3    Suissa, S.4
  • 16
    • 55549124570 scopus 로고    scopus 로고
    • ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
    • American College of Cardiology Foundation. PMID: 18853965
    • Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al; American College of Cardiology Foundation. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008;103:2890-907. [PMID: 18853965]
    • (2008) Am J Gastroenterol , vol.103 , pp. 2890-2907
    • Bhatt, D.L.1    Scheiman, J.2    Abraham, N.S.3    Antman, E.M.4    Chan, F.K.5    Furberg, C.D.6
  • 17
    • 0141483373 scopus 로고    scopus 로고
    • Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions
    • PMID: 14556868
    • Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930-5. [PMID: 14556868]
    • (2003) Am J Cardiol , vol.92 , pp. 930-935
    • Kinnaird, T.D.1    Stabile, E.2    Mintz, G.S.3    Lee, C.W.4    Canos, D.A.5    Gevorkian, N.6
  • 19
    • 39349101029 scopus 로고    scopus 로고
    • Immortal time bias in pharmaco-epidemiology
    • PMID: 18056625
    • Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-9. [PMID: 18056625]
    • (2008) Am J Epidemiol , vol.167 , pp. 492-499
    • Suissa, S.1
  • 21
    • 0042780283 scopus 로고    scopus 로고
    • Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial
    • Clopidogrel for the Reduction of Events During Observation Investigators PMID: 12925453
    • Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al; Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003;108:921-4. [PMID: 12925453]
    • (2003) Circulation , vol.108 , pp. 921-924
    • Saw, J.1    Steinhubl, S.R.2    Berger, P.B.3    Kereiakes, D.J.4    Serebruany, V.L.5    Brennan, D.6
  • 22
    • 34447312473 scopus 로고    scopus 로고
    • Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial
    • CHARISMA Investigators. PMID: 17659194
    • Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, et al; CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007;50:291-5. [PMID: 17659194]
    • (2007) J Am Coll Cardiol , vol.50 , pp. 291-295
    • Saw, J.1    Brennan, D.M.2    Steinhubl, S.R.3    Bhatt, D.L.4    Mak, K.H.5    Fox, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.